The Institute for Precision Medicine hosts a monthly lecture series to highlight advances in precision medicine research and personalized care both at Pitt/UPMC and nationwide. This month, we are excited to host Amanda Paulovich, MD, PhD as a guest speaker. Dr Paulovich is the Aven Foundation Endowed Chair, and Director, CLIA Targeted Proteomic Laboratory at Fred Hutchinson Cancer Research Center. She also serves as the Director of the Clinical Research Proteomics Platform at the Brotman Baty Institute for Precision Medicine and is Professor of Medicine in the divison of Oncology at the Unviersity of Washington School of Medicine.
Dr. Paulovich received her M.D. and Ph.D. with Dr. Lee Hartwell at the University of Washington. She completed a residency in Internal Medicine at Massachusetts General Hospital and a fellowship in Oncology at Dana-Farber/Partners Cancer Center in Boston. She completed postdoctoral training at MIT-Whitehead Center for Genomics Research working with Dr. Eric Lander. As an oncologist, Dr. Paulovich was struck by the paucity of quantitative assays for measuring clinically relevant phenotypes in her patients, and the limitations that this put on her ability to practice “personalized medicine.” Out of these experiences, she became passionate about developing technologies and strategies for translation of novel diagnostics and therapeutics to enable precision medicine. Over the past 18 years, Dr. Paulovich’s research has focused on relieving a roadblock in biomedical research: a lack of validated and standardized tools for reliably quantifying human proteins. She has developed quantitative proteomic assays for measuring immunotherapy response, DNA damage response and growth factor receptor signaling to name a few. She was inducted to American Society for Clinical Investigation, received the 2014 Life Science Innovation Northwest Women to Watch in Life Science Award, received the 2015 Distinguished Achievement in Proteomic Sciences Award from the Human Proteome Organization, was awarded the Aven Foundation Endowed Chair in 2018, and was appointed Director of the Clinical Research Proteomics Platform of the Brotman Baty Institute for Precision Medicine in 2019.
In her presentation Dr Paulovich will discuss the added value of proteogenomics to the current genome-driven approach to precision oncology, and summarize the growing incorporation of targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry into clinical trials and the clinical laboratory. The establishment of proteogenomics represents an important component towards implementation of broader precision medicine efforts in cancer and beyond. See also: Nat Rev Clin Oncol. 2019, 16(4):256-268 (PMID: 30487530) and Cell. 2021, 184(7):1661-1670 (PMID: 33798439).
Please mark your calendars for June 23rd at 4:00pm, and register to join the conference at the following link: